OCT1 genetic variants influence the pharmacokinetics of morphine in children

Pharmacogenomics

Volumn 14, Issue 10, 2013, Pages 1141-1151

  Fukuda, Tsuyoshi ^a,b   Chidambaran, Vidya ^a,b   Mizuno, Tomoyuki ^a   Venkatasubramanian, Raja ^a   Ngamprasertwong, Pornswan ^a,b   Olbrecht, Vanessa ^a,b   Esslinger, Hope R ^a   Vinks, Alexander A ^a,b   Sadhasivam, Senthilkumar ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

children; morphine; OCT1; pediatrics; pharmacogenetics; pharmacokinetics; population pharmacokinetics; surgical pain

Indexed keywords

MORPHINE; ORGANIC CATION TRANSPORTER 1;

ADENOTONSILLECTOMY; ADOLESCENT; AFRICAN AMERICAN; ANALGESIA; ARTICLE; BAYES THEOREM; BODY WEIGHT; CAUCASIAN; CHILD; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONFORMATION; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; ORGANIC CATION TRANSPORTER 1 GENE; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; WILD TYPE; GENETIC POLYMORPHISM; GENETICS; POSTOPERATIVE PAIN;

AFRICAN AMERICANS; CHILD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MORPHINE; ORGANIC CATION TRANSPORTER 1; PAIN, POSTOPERATIVE; POLYMORPHISM, GENETIC;

EID: 84880461226     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.94     Document Type: Article

References (28)

1. Quality improvement guidelines for the treatment of acute pain and cancer pain. American Pain Society Quality of Care Committee. JAMA 274(23), 1874-1880 (1995).
2. Anderson BJ, Holford NH. Tips and traps analyzing pediatric PK data. Paediatr. Anaesth. 21(3), 222-237 (2011).
3. Edwards RR, Doleys DM, Fillingim RB, Lowery D. Ethnic differences in pain tolerance: Clinical implications in a chronic pain population. Psychosom. Med. 63(2), 316-323 (2001). (Pubitemid 32249957)
4. Edwards RR, Moric M, Husfeldt B, Buvanendran A, Ivankovich O. Ethnic similarities and differences in the chronic pain experience: A comparison of African-American, Hispanic, and white patients. Pain Med. 6(1), 88-98 (2005). (Pubitemid 40361227)
5. Rahim-Williams FB, Riley JL, Herrera D, Campbell CM, Hastie BA, Fillingim RB. Ethnic identity predicts experimental pain sensitivity in African-Americans and Hispanics. Pain 129(1-2), 177-184 (2007). (Pubitemid 46551380)
6. Sadhasivam S, Chidambaran V, Ngamprasertwong P et al. Race and unequal burden of perioperative pain and opioid related adverse effects in children. Pediatrics 129(5), 832-838 (2012).
7. Sadhasivam S, Krekels EH, Chidambaran V et al. Morphine clearance in children: Does race or genetics matter? J. Opioid. Manag. 8(4), 217-226 (2012).
8. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos. 25(1), 1-4 (1997). (Pubitemid 27045126)
9. Knibbe CA, Krekels EH, Danhof M. Advances in paediatric pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 7(1), 1-8 (2011).
10. Tzvetkov MV, Stingl JC, Brockmoller J. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in the OCT1 gene affect morphine pharmacokinetics. Clin Pharmacol. Ther. 91(Suppl. 1), S105 (2012).
11. Jonker JW, Schinkel AH (Pubitemid 38090693)
12. Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch. 447(5), 666-676 (2004). (Pubitemid 38241452)
13. Nies AT, Koepsell H, Winter S et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50(4), 1227-1240 (2009).
14. Gorboulev V, Ulzheimer JC, Akhoundova A et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16(7), 871-881 (1997). (Pubitemid 27332696)
15. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 51(6), 913-921 (1997). (Pubitemid 27249124)
16. Saadatmand AR, Tadjerpisheh S, Brockmoller J, Tzvetkov MV. The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem. Pharmacol. 83(10), 1427-1434 (2012).
17. Kerb R, Brinkmann U, Chatskaia N et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12(8), 591-595 (2002). (Pubitemid 36005667)
18. Shu Y, Sheardown SA, Brown C et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117(5), 1422-1431 (2007). (Pubitemid 46718430)
19. Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmoller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J. 12(1), 22-29 (2012).
20. Tzvetkov MV, Saadatmand AR, Lotsch J, Tegeder I, Stingl JC, Brockmoller J. Genetically polymorphic OCT1: Another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin. Pharmacol. Ther. 90(1), 143-150 (2011).
21. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 9(4), 242-247 (2009).
22. Tzvetkov MV, Vormfelde SV, Balen D et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther. 86(3), 299-306 (2009).
23. Clavijo CF, Hoffman KL, Thomas JJ et al. A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 400(3), 715-728 (2011).
24. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: Problems and solutions. AAPS J. 11(3), 558-569 (2009).
25. Sadhasivam S, Chidambaran V. Pharmacogenomics of opioids and perioperative pain management. Pharmacogenomics 13(15), 1719-1740 (2012).
26. Po HN, Senozan NM. The Henderson-Hasselbalch equcation: Its histroy and limitaions. J. Chem. Educ. 78(11), 1499-1503 (2001). (Pubitemid 33607487)
27. Shu Y, Brown C, Castro RA et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83(2), 273-280 (2008).
28. Zelcer N, van de Wetering K, Hillebrand M et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc. Natl Acad. Sci. USA 102(20), 7274-7279 (2005). (Pubitemid 40696369)